February 18, 2025
February 18, 2025 – Durham, North Carolina: ScitoVation, a pioneer in New Approach Methodologies (NAMs), today announced a strategic decision to fully focus on advancing software tools and computational services to help clients assess the safety of compounds (in silico). By directing attention to its core strengths, ScitoVation aims to bolster its competitive edge and deliver even greater value to the chemical and pharmaceutical industries.
As part of this transition, the company will conclude its laboratory operations at the end of March 2025. ScitoVation remains committed to fulfilling all existing lab-based projects and ensuring a seamless transition for its clients.
“For years, our lab has played a crucial role in advancing cell-based and genotoxicity research, contributing valuable insights to the scientific community,” said Dr. Sammy Orelien, CEO of ScitoVation. “However, as the field of toxicology moves increasingly toward computational approaches, we believe that focusing on what we do best—delivering next-generation in silico solutions—will yield more significant benefits for both our clients and our stakeholders. This strategic pivot capitalizes on the strong margins and growth potential of our computational offerings, allowing us to optimize resource allocation and enhance shareholder value.”
Building on its expertise in pharmacokinetics (PBPK) and transcriptomics, ScitoVation is preparing to launch an advance platform designed to enhance decision-making and streamline chemical risk assessment. Additional details will be shared in the coming weeks.
For inquiries regarding the lab transition, please contact:
jorelien@scitovation.com
About ScitoVation
ScitoVation is a leader in applying New Approach Methodologies (NAMs) to help clients assess the safety of compounds. With a deep focus on computational toxicology, the company empowers researchers and regulators to make more informed decisions, accelerating innovation in the chemical and pharmaceutical industries.
© 2025 ScitoVation. All rights reserved.